Compugen : Corporate Presentation

Corporate Overview For investors and analysts

A u g u s t 2 0 2 6

Our Vision

Transforming patient lives by developing first-in-class therapeutics based on Compugen's AI/ML-powered computational target discovery platform UnigenTM

From Code to Cure®

3

Focus on novel immuno- oncology antibodies

Di s covere d by Com puge n 's com putati onal d i scover y p l atfor m - U n i ge n T M

Rich clinical pipeline with validating partnerships >$1bn in milestones PLUS royalties

Fully-owned Clinical Assets

COM701

Potential 1st in-class Anti-PVRIG antibody

COM902

Fc-reduced anti-TIGIT antibody

Phase 3 AstraZeneca program

Rilvegostomig

AZ est. >$5bn PYR1

anti-PD1/TIGIT bispecific Ab, TIGIT component derived from COM902

Phase 1 licensed to Gilead

GS-0321 (previously COM503)2

Potential first-in-class Anti-IL-18BP antibody

Early-stage pipeline Multiple assets

in research undisclosed

Cash balance $125.3M as of June 30, 2026

Expected cash runway into 2029 to support operations

COM701 MAIA-ovarian interim analysis projected by Q1 2027 Advancement of GS-0321 Phase 1 trial

Advancement early-stage pipeline

4

1. PYR: AstraZeneca 's guidance from 2024 Investor Day for non-risk adjusted peak year revenue for rilvegostomig inclusive of all indications and excludes non-registrational trials

2. Compugen responsible for preclinical development and first- in-human Phase 1 trial evaluating the safety and tolerability of GS-0321. Thereafter, Gilead will have sole right to develop and commercialize GS-0321.

Immuno-oncology pipeline focus on novel antibodies

MAIA-ovarian COM701 maintenance therapy (anti-PVRIG

antibody)

Adaptive platform trial: relapsed platinum sensitive

ovarian cancer, sub-trial 1 randomized vs. placebo

GS-0321

(anti-IL18BP antibody)

Phase 1: solid tumors

Programs

(mechanism of action)

Stage and Indication

Sponsor/

Partner

Rilvegostomig monotherapy and combination trials

(anti-PD1/TIGIT antibody)

TIGIT component derived from COM902

12 Phase 3 across multiple indications

14 Phase 1 or 2: NSCLC, GI cancer, others

Early-stage pipeline

(potential first-in-class drugs/new mechanism of actions)

Undisclosed

CT.gov ; AstraZeneca Clinical Trial appendix

5

GS-0321: Compugen responsible for preclinical development and the first- in-human Phase 1 trial evaluating the safety and tolerability of GS-0321. Thereafter Gilead will have the sole right to develop and commercialize GS-0321.

Rilvegostomig broad AstraZeneca development strategy as IO backbone for future combinations

Rilvegostomig broad Phase 3 development program

Pote nti a l refl e c t >$ 5 B PYR ta rget*

Study name

Indication

Rilvegostomig monotherapy or in combination

Data anticipated

ARTEMIDE-Lung02

squamous NSCLC 1L PD-L1 ≥1%

rilvegostomig + chemo vs pembro + chemo

>2027

Lung

ARTEMIDE-Lung03

ARTEMIDE-Lung04 TROPION-Lung10

non-sq NSCLC 1L PD-L1 ≥1%

metastatic NSCLC 1L PD-L1 ≥50%

non-sq NSCLC 1L PD-L1 ≥50% w/o actionable genomic alterations

rilvegostomig + chemo vs pembro + chemo mono vs pembro

rilvegostomig ± TROP2 ADC (Datroway) vs pembro

>2027

>2027

>2027

ARTEMIDE-Biliary02

1L advanced BTC

rilvegostomig + chemo vs durvalumab + chemo

>2027

Gastrointestinal

ARTEMIDE-Biliary01 ARTEMIDE-Gastric01

ARTEMIDE-HCC01

adjuvant BTC

1L gastric cancer HER2+ 1L HCC

rilvegostomig + chemo vs chemo

rilvegostomig + Enhertu + chemo vs rilvegostomig + Herceptin + chemo vs pembro + Herceptin + chemo

rilvegostomig + anti-VEGF ( Avastin) ± anti-CTLA4 (Imjudo) vs Avastin + atezo

>2027

>2027

>2027

DESTINY-BTC01

1L HER2+ BTC

Enhertu ± rilvegostomig vs chemo + durvalumab

>2027

CLARITY-Gastric 02

1L CLDN18.2+ HER2-, gastric & gastroesophageal junction

Sonesitatug vedotin + rilvegostomig/Nivo + chemo vs Nivo + chemo

>2027

Other

DESTINY- Endometrial01 TROPION-Urothelial04

stg III/IV/recurrent endometrial cancer

high-risk muscle invasive urothelial carcinoma

rilvegostomig + Enhertu vs pembro + Enhertu vs pembro + chemo rilvegostomig + Datroway vs Datroway vs nivo or durva or pembro + EV

>2027

>2027

12 phase 3 trials across multiple indications

Trials announced by AstraZeneca- CT.gov; AstraZeneca Clinical Trial Appendix., not comprehensive, does not include investigator-initiated studies 7

*AstraZeneca's guidance from 2024 Investor Day; non-risk adjusted peak year revenue target inclusive of all indications and excludes non-registrational trials

Rilvegostomig: Significant value creation potential

Rilvegostomig

AZ est. >$5bn PYR1

PD-1/TIGIT bispecific Ab

Compugen eligible to receive up to

$195m in additional milestone payments & tiered royalties up to mid-single digit

AZ dual checkpoint inhibitor bispecific: to replace anti-PD-(L)1's and be the backbone for future combinations

AZ 12 pivotal trials: novel combinations across NSCLC, GI, Endometrial, Eurothelial Cancers

Promising Phase 1/2 data presented: ARTEMIDE-01, GEMINI Gastric,

TROPION-Lung04, GEMINI-Hepatobiliary TROPION-PanTumor 03, Destiny-Gastric 03

$105M received (upfront payments, milestones, monetization of small royalty portion)

AstraZeneca has rights to develop TIGIT bispecifics

Compugen retains rights to PVRIG (PVRL2)/TIGIT bispecifics

8

1. AstraZeneca Q2 2026, presentation; PYR: AstraZeneca 's estimated non-risk adjusted peak year revenue for rilvegostomig inclusive of all indications and excludes non-registrational trials

Not all anti- TIGIT antibodies are created equally

Anti body for m at m atte rs

Anti-PD-1 Fab

from COM902

Anti-TIGIT Fab

• Bispecific approach differentiated: coordinated inhibition of PD-1/TIGIT induces greater ex vivo activity than its components1

-2.5 0.0 2.5 5.0

Patient

Log2(Fold Change - IFNy)

Rilvegostomig 54

Program by:

aPD-1 + aTIGIT (bivalent) aPD-1 + aTIGIT (monovalent)

Pembrolizumab

aPD-1 (bivalent) aTIGIT (bivalent)

43

39 P=0.15

37 P=0.09

39 P=0.15

9 P=2.6e-5

PD-L1 TPS 1 5

10 15 20

25 30

35 40

45 0 20 40 60

(PD-1/TIGIT)

PD-L1 TPS <1 1-49 ≥50 Pending

% tumors with activity

Rilvegostomig (IgG1-mut Fc reduced)

Rilvegostomig, an Fc-reduced, monovalent, bispecific humanized IgG1 monoclonal antibody targeting PD-1 and TIGIT. The anti-TIGIT component of rilvegostomig is derived from COM902 developed by Compugen

• Fc attenuated triple -mutant IgG1 potentially maintaining and enhancing immune responses, and conferring improved safety 1

• Fc-reduced functionality important for efficacy - unmodified or enhanced Fc-functionality appears to be detrimental to rilvegostomig anti-tumour activity in NSCLC explants1

  
  
  

  9

  *Compugen is eligible for milestone and up to mid single digit tiered royalty payments

  1. https://www.astrazeneca.com/content/dam/az/Investor_Relations/events/AZN-2025-ESMO-brochure.pdf

COM701 - potential first-in-class anti-PVRIG antibody

COM 701 potential 1 st in c lass anti- PVRIG antibody

COM701 POTENTIAL FIRST-IN-CLASS

Phase 1 data presented; proof-of-concept studies ongoing

COM701

IgG4

Avoids CD8 + T cell depletion and potential associated risks

BioNtech

BNT3213* (formally PM1009 acquired from Biothesus)

Simcere

SIM-0348*

PHASE 1

Data presented

D3 Bio

D3L-0012*

FutureGen

FG-B902/T903*

TG ImmunoPharma

NM1F

Hengrui

SHR-2002*

Shanghai Junshi

JS-209*

PHASE 1 and 2

No data presented

PRE-CLINICAL

11

*Bi-specifics

The preclinical list of players is not exhaustive

Strong biological rationale to target PVRIG in ovarian cancer

• High PVRIG pathway expression levels in ovarian cancer

• PVRIG pathway differentially expressed on early differentiated stem like memory T cells and dendritic cells compared to other immune checkpoints

• PVRIG blockade with COM701 alters the tumor microenvironment including in less inflamed tumors like ovarian cancer

12

Alteber et al, Cancer Immunology Research, 2024

COM 701 showed c l inical benefit in patients with hard- to- t reat platinum resistant ovarian cancer Ty p i cal l y, n o t r e sp o n d i n g to i m m u n ot h e ra py 1 -3

Patient characteristics

Encouraging durable responses as monotherapy and in combination

Safety and tolerability profile in combination consistent with anti-PD-(L)1s7-8

Platinum resistant ovarian cancer Heavily pretreated

Some patients failed ADCs

Across PD-L1 tumor expression level

Single agent COM701 activity4-6

PR >18 months in immune desert patient Immune modulation of the TME

Triple combination blocking PVRIG, TIGIT, PD-17-9

ORR 17-20%* DCR 45-46% (n=44)

mPFS in patients with CB 10.5 months Responses across PD-L1 levels, supportive of COM701 mediated effect

Most common adverse events grade 1/2 fatigue, diarrhea, nausea

Grade ≥3 treatment related adverse events 20%

No grade 4/5 treatment related adverse events

Treatment related discontinuations 4.4%

1. Matulonis et al, ASCO 2022,

2. Holmes et al, JCO ASCO 2022,

   
   
   

3. Perets et al, ACCR 2022

4. Ophir E et al, SITC 2022

5. Alteber E et al, Cancer Immunology Research 2024

6. Vaena et al, ASCO 2021

7. Gaillard S et al, SITC 2023

8. Yeku et al, SITC 2024

9. Yeku et al, ESMO 2025

PR: Partial Response; CR: Complete Response; ORR: Overall Response Rate; DCR: Disease Control Rate;

ADCs: Antibody Drug Conjugates TME: Tumor Microenvironment CB: Clinical Benefit

13

*anti-PD-1 ± anti-TIGIT (ORR <10% all-comers, 0% PD-L1 <1)1-3

Strong c l inical and biological rationale to advance COM 701 development to platinum sensitive ovarian cancer

High PVRIG pathway expression levels in ovarian cancer and PVRIG unique biology differentiated from other checkpoints supporting activity in less inflamed tumors1

COM701 showed clinical benefit in hard-to-treat platinum resistant ovarian cancer patients including PD-L1 low expressing tumors1-6

Platinum sensitive ovarian cancer patients are less heavily pre-treated, less immune compromised7-8

Platinum based chemotherapy may reduce disease burden and sensitize tumors to COM701's unique mechanism of action9

COM701 is well tolerated and associated with durable responses especially important in a maintenance setting1-6

Platinum sensitive ovarian cancer represents a less competitive landscape to platinum resistant ovarian cancer

Platinum sensitive ovarian cancer represents a less competitive landscape to platinum resistant ovarian cancer

1. Alteber et al, Cancer Immunology Research, 2024

   
   
   

2. Vaena et al, ASCO 2021

3. Ophir E et al, SITC 2022

4. Gaillard S et al, SITC 2023

5. Yeku et al, SITC 2024

6. Yeku et al, ESMO 2025

7. Hanker LC, et al, Ann Oncol. 2012;23(10):2605-12.

8. González-Martín et al, Ann Oncol . 2023

   Oct;34(10):833-848

   14

9. Lanickova et al, Clin Cancer Res; 2025

MAIA- ovarian: adaptive t r ia l with maintenance COM 701 therapy in relapsed platinum sensitive ovarian cancer

K e y e l i g i b i l i t y c r i t e r i a

Relapsed platinum sensitive ovarian cancer

Complete or partial response following platinum-based chemotherapy

Maintenance therapy post bevacizumab and/or PARP inhibitor or not a candidate for bevacizumab and/or PARP inhibitor

Presence of liver metastases excluded

Sub-trial 1

Single agent activity of COM701

versus placebo (standard of care)

Adaptive trial n= 60 2:1 Randomization

Sub-trial 2 and beyond

COM701 combination studies e.g.

anti-PD-1/TIGIT or bevacizumab or PARPi or others

E n d p o i n t s

Primary: Efficacy- median progression free survival

Secondary: Safety

Exploratory: Biomarkers

T i m e l i n e s : s u b - t r i a l 1

Trial initiation: Q2 2025

First patient dosed: July 2025

Projected Interim analysis: Q1 2027

Evaluation of COM701 single agent activity, combinations and contribution of effects, represents a regulatory and commercial opportunity

Evaluation of COM701 single agent activity, combinations and contribution of effects, represents a regulatory and commercial opportunity

15

https://clinicaltrials.gov/study/NCT06888921?cond=COM701&rank=1

Advancing COM 701 to address unmet need in PSOC

B u i l d i n g on d ata ge n e rate d i n P RO C

Platinum Sensitive Ovarian Cancer (PSOC)

Platinum free ≥6-month before relapse

Platinum Resistant Ovarian Cancer (PROC)

Platinum free <6-month before relapse

Immune system more compromised and immunotherapy response more challenging

1L 1st Relapse

2nd Relapse

~

2L 3L

3rd Relapse

4th Relapse

5th Relapse

Standard of care treatment options

COM701 opportunity:

Delay transition to platinum-resistant disease

NO APPROVED TREATMENT OPTIONS

4L 5L

6L

Diagnosis/Surgery

Platinum doublet +/ - Bevacizumab

Maintenance Bevacizumab or PARPi

Platinum doublet +/- bevacizumab

Maintenance Bev or PARPi or NONE

Platinum doublet

Maintenance NONE

Potential benefits of COM701:

Longer time before progression Recovery break from chemotherapy

Delay transition to PROC

Preserve additional treatment options

16

G S - 0 3 2 1 ( p r ev i ou s l y CO M 5 0 3 ) - p ote nt i a l f i rst - i n - c l as s a nt i - I L 1 8 B P an t i b o d y GS- 0321 : Compugen identified potential dominant immunosuppression mechanism and antibody therapeutic

I n t e r l e u k i n - 1 8 b i n d i n g p r o t e i n , a n e n d o g e n o u s i n h i b i t o r o f i n t e r l e u k i n - 1 8

Myeloid/

Cancer cells

DAMPs

Inflammasome

IL-18 immune stimulatory cytokine

upregulated in tumor microenvironment

IFNγ

Pro-IL-18

IL-18BP

IL-18BP blocks IL-18 activity

IL-18

MγD88

IL-18R

GS-0321

GS-0321 potential first-in-class

high affinity antibody releases IL-18 to enhance T and NK cell activation in the tumor

T/NK cells

DAMPs- Damage-associated molecular patterns . GS-0321 is licenced to Gilead, Compugen responsible for ongoing preclinical and future Phase 1 development, Thereafter, Gilead will have sole right to develop and commercialize GS-0321

18

GS- 0321 differentiated approach to harness cytokine biology

L i c e n s e a g r e e m e n t w i t h

Key Benefits

Highlights potential of GS-0321 differentiated approach to harness cytokine biology to treat cancer

Reflects quality of our computational capabilities & ability to advance discoveries into drugs candidates

Strengthens our balance sheet

Advances our vision to bring potential 1st in class therapies to patients

up to $848M deal value

Signed December 2023

$60 million upfront and $30 million milestone payment on

achieving IND clearance, received*

Up to additional $758M in additional development, regulatory and commercialization future milestone payment

Single-digit to low double-digit tiered royalties on WW future net sales

Compugen responsible for preclinical and ongoing Ph 1 trial initiated in Q4 2024. Thereafter, Gilead will have sole right to develop and commercialize GS-0321

19

* less 15% tax withheld at source

GS- 0321 : advantages of a differentiated approach

GS-0321 anti-IL-18 binding protein Recombinant cytokines

Novelty

Novel antibody approach

Multiple challenges, no FDA approval in last 30 years

Anti-IL-18BP releases endogenous IL-18 in the TME Systemic administration of a recombinant protein

Pharmacokinetics

Slow elimination

Requires modification/engineering to overcome pharmacokinetic limitations

Immunogenicity

Potentially low risk, human IgG antibody

Modified/engineered recombinant cytokine, increases risk

Therapeutic window

Immune modulation selectively targets TME, potential for better tolerance

Systemic immune modulation, potential for unmanageable side effects

20